Roche’s Actemra Scores New Indication In Rare Autoimmune Disease
SSc-ILD Indication Comes With Biosimilar Competition On The Horizon
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.
You may also be interested in...
Certa’s lead candidate has shown promise in a mid-stage trial for the rare but debilitating skin disorder, triggering pivotal development plans to address the high unmet need.
Plus Pfizer/BioNTech report real-world data from Israel on its vaccine, while Roche’s Actemra misses Phase III endpoint in another combo study with Veklury.
Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).